<DOC>
	<DOCNO>NCT02459665</DOCNO>
	<brief_summary>This pilot study prepare large clinical trial . Sixty HIV-negative , non-pregnant , sexually active woman age 18-45 bacterial vaginosis ( BV ) Amsel criterion and/or Trichomonas vaginalis ( TV ) wet mount culture treat use oral metronidazole 7 day . After successful treatment , free vaginal candidiasis , curable sexually transmit infection ( STIs ) urinary tract infection ( UTI ) ) , randomise 4 different vaginal microbiome ( VMB ) maintenance intervention ( 15 per group ) within 3 day complete oral metronidazole treatment : 1 ) Behavioral 'vaginal practice cessation safer sex ' counselling ( control ) ; 2 ) Behavioral counsel plus 500mg metronidazole pill twice per week two month ; 3 ) Behavioral counsel plus Ecologic Femi vaginal capsule , per day 5 day immediately oral metronidazole treatment follow thrice weekly , two month ; 4 ) Group 4 : Behavioral counsel plus Gynophilus vaginal tablet , every 4 day two month . In 3 biomedical intervention group , vaginal product use may cease temporarily menstruation . Participants ask adhere intervention 2 month , VMB assessment take place ( screen enrolment visit ) , ( Day 7 , Month 1 Month 2 visit ) , intervention ( Month 6 visit ) .</brief_summary>
	<brief_title>Rwanda VMB Restoration Study</brief_title>
	<detailed_description />
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Sexually active , defined sex least twice two week prior screen At high risk HIV/STIs/BV , define one sexual partner last 12 month OR treat STI and/or BV last 12 month Successfully treat BV ( Amsel criterion ) TV , free STIs , symptomatic vaginal candidiasis UTI enrollment Currently good physical mental health judge study physician Willing able adhere study procedure provide write informed consent . Pregnant HIV positive Clinicianobserved genital ulcer , condylomata , genital abnormality screen enrollment Underwent gynaecological surgery/invasive procedure 3 month prior screen History significant urogenital prolapse , undiagnosed vaginal bleeding , urine faecal incontinence , blood clot disorder Allergic metronidazole component study drug Not willing stop use oral vaginal probiotic screen visit end study participation Participating another health intervention study For reason potentially interfere participant safety protocol adherence judge Principal Investigator</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>